---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-107164"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T03:53:33.085447+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences prices $3.0M public offering at $0.33/unit; warrants amended

## Summary
- Offering of 9.1M units at $0.33/unit; each unit: 1 share (or pre-funded warrant) + 1.5 warrants exercisable at $0.33.
- Net proceeds ~$2.8M; expected use: Lap-Band marketing, ReShapeCare development, working capital.
- Existing warrants for ~1.35M shares amended to $0.33 exercise price upon closing.
- Closing expected Oct 3, 2023; Maxim Group sole placement agent with 7% fee plus placement agent warrants.

## SEC filing metadata
- accession: 0001104659-23-107164
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000110465923107164/0001104659-23-107164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000110465923107164/tm2327726d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-107164
- JSON: https://secwatch.observer/filing/0001104659-23-107164.json
- Plain text: https://secwatch.observer/filing/0001104659-23-107164.txt

## Key facts
- Material Agreements
  Vyome Holdings, Inc entered into Securities Purchase Agreement with certain investors valued at approximately $2.8 million (effective 2023-09-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: approximately $2.8 million
  - Effective: 2023-09-29
  source text: On September 29, 2023, ReShape Lifesciences Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Investors")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000110465923107164/0001104659-23-107164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.